Your ANSwer for Workers' Compensation Medical Cost Containment

Call Us Today!|info@ans-solutions.com
  • drug utilization
    Permalink Gallery

    Government Struggles to Hold Opioid Manufacturers Accountable

Government Struggles to Hold Opioid Manufacturers Accountable

For the first time ever, the U.S. DEA targeted a prescription drug manufacturer for their role in black market opioids and damages incurred. Mallinckrodt Pharmaceuticals, one of the largest national manufacturers of the highly addictive generic painkiller oxycodone, one of the leading drugs responsible for the more than 15,000 overdose deaths in 2015, was accused of shirking its responsibility to report suspicious drug orders.

Who’s to Blame For The Opioid Epidemic?

Created at Mallinckrodt’s Hobart, NY facility, oxycodone shipped via its distributor network, including KeySource, Sunrise Wholesale and Cardinal […]

By |July 24th, 2017|Clinical Alert, Drug Utilization Review, Pharmaceutical Industry|Comments Off on Government Struggles to Hold Opioid Manufacturers Accountable

Medical Marijuana Vs. Big Pharma

Increasingly gaining ground as an accepted medicine by top health associations, researchers, and medical journals, the marijuana industry continues its massive expansion, with legalization encompassing more than half the U.S. Predicted to expand nationwide by 2021 by investment firm The Motley Fool, other sectors of the economy are feeling the strain of the industry’s new growth – but no one greater than Big Pharma.

Marijuana & Pharmaceutical Market Share
In an effort to determine how cannabis cash flow is effecting the pharmaceutical industry, researchers at the University of Georgia uncovered just […]

By |June 14th, 2017|Drug Utilization Review, Pharmaceutical Industry|Comments Off on Medical Marijuana Vs. Big Pharma
  • prescription drugs ANS pharmacotherapy review
    Permalink Gallery

    Alabama Doctor Arrested In Connection with Matt Roberts of 3 Doors Down Overdose Death

Alabama Doctor Arrested In Connection with Matt Roberts of 3 Doors Down Overdose Death

In mid-August of this year, fans were stunned by the death of 38-year-old Matt Roberts, former guitarist of 3 Doors Down. Alabama physician Dr. Richard Snellgrove was arrested November 16th for allegedly providing the rocker with drugs outside the course of his professional practice. Snellgrove prescribed some five different medications, including methadone, hydrocodone, lorazepam and fentanyl — all prescribed in the names of different individuals, but intended for Roberts.

Slated to perform at a charity event for veterans, the rocker’s father, Darrell Roberts, who often traveled […]

By |December 22nd, 2016|Opioid Abuse, Pharmaceutical Industry, Pharmacotherapy Review|Comments Off on Alabama Doctor Arrested In Connection with Matt Roberts of 3 Doors Down Overdose Death
  • Permalink Gallery

    New FDA Warning: Avoid Prescribing Opioids & Benzos Together

New FDA Warning: Avoid Prescribing Opioids & Benzos Together

In a recent announcement by the FDA, boxed warning labels will now be required to advise against the utilization of prescription opioid pain medicines alongside benzodiazepines unless no other adequate alternative treatment method exists. Warnings about the risks of combining these two classes of drugs are nothing new. Already required on drug warning labels, additional black box warnings are an effort by the FDA to reach out to those who may have “missed the message.”

Classified as Central Nervous System (CNS) depressants, each drug alone can trigger side effects such […]

By |November 21st, 2016|Pharmaceutical Industry, Pharmacotherapy Review|Comments Off on New FDA Warning: Avoid Prescribing Opioids & Benzos Together

How Common is Illegal Drug Use Among Pain Patients?

At the American Pain Society’s 35th Annual Scientific Meeting in Austin, findings were released on the use of illicit substances among chronic pain patients. Of 450,081 patients included in a study by Baltimore-based pain medication monitoring firm Ameritox, 10.4% of urine samples tested positive for the use of at least one illicit substance.

How Many of Those Identified Were Workers Comp Patients?
Workers compensation was the primary payer for 22,525 of the 450,081 patients in the study, conducted between January 2013 and July 2015, which showed the use of illicit substances […]

  • Permalink Gallery

    CDC Opioid Guidelines Sheds Light on Conflicting Expert Opinions

CDC Opioid Guidelines Sheds Light on Conflicting Expert Opinions

The CDCs latest opioid prescribing guidelines, released this March, were created with the goal of achieving balance between the analgesic and addictive properties of opioid analgesics, to uphold the safety as well as meet the pain management needs of the public at large. Unfortunately, the controversy surrounding these guidelines points to a detrimental issue at the crux of their implementation: A fractured field – two expert, yet conflicting, schools of thought on the current opioid policy.

  • Treating chronic pain with a wider range of treatments, as opposed to relying mainly […]
By |May 31st, 2016|Pharmaceutical Industry, Pharmacotherapy Review|Comments Off on CDC Opioid Guidelines Sheds Light on Conflicting Expert Opinions
  • ANS Pharmacotherapy Reivew fights the nation's opioid epidemic
    Permalink Gallery

    Abuse Deterrent Opioids a New Era of Opioid Drug Development

Abuse Deterrent Opioids a New Era of Opioid Drug Development

The prevalence of opioid use and abuse has led to a new era of opioid drug development: Abuse deterrent (AD) opioids.

The goal?….

Maintain the efficacy of opioid formulations while improving their ability to deter abuse. Following guidelines developed by the FDA to categorize new opioid formulations, pharmaceutical companies are now on a quest to develop tomorrow’s safety net against opioid abuse.

How will the FDA be categorizing these new AD opioid formulations?

  1. Physical/chemical barriers
    Physical barriers that prevent the crushing, cutting, grating, grinding, or chewing of opioid formulations, alone or in combination […]

By |January 15th, 2016|Drug Utilization Review, Opioid Abuse, Pharmaceutical Industry|Comments Off on Abuse Deterrent Opioids a New Era of Opioid Drug Development

The Perils of Polypharmacy

Pharmacotherapy review reduces costs and minimizes risks present by polypharmacyIn the context of large loss workers compensation claims and the treatment of pain in injured workers, polypharmacy is typically associated with the use of four or more medications. As a result, polypharmacy creates an environment where several complications can occur. Here we delve into some critical issues affecting the injured worker as a result of polypharmacy: compliance, drug interaction and risk of addiction.

Dosage Compliance & Drug Interactions

To put it […]

By |November 30th, 2015|Opioid Abuse, Pharmaceutical Industry, Pharmacotherapy Review|Comments Off on The Perils of Polypharmacy

ANS Solutions Exhibiting at the National WC & Disability Conference & Expo – Booth #646

National WC & Disability Conference - ANS Solutions 2015 Conference ScheduleANS Solutions, one of the top healthcare cost management companies, will be exhibiting at the National Workers Compensation & Disability Conference & Expo November 11-13, 2015, Booth #646.

For anyone involved in the workers’ compensation and disability management industries, the National WC & Disability Conference is the ultimate ground for new learning and networking with like-minded professionals. The event will be taking place at Mandalay Bay in Las Vegas from November […]

By |October 26th, 2015|Medical Cost Containment, Pharmaceutical Industry, Workers Compensation Payers|Comments Off on ANS Solutions Exhibiting at the National WC & Disability Conference & Expo – Booth #646

Advanced Strategies for Pharmaceutical Cost Management

Pharmacuetical Cost ContainmentWith large loss claims, the road to managing the hefty costs associated with pharmaceutical therapies can be long and winding. As more drugs become available within drug classes, there is often a large cost disparity among medications. Further, patient access to more affordable and equally (if not more) effective medications is limited. Fortunately, there are advanced pharmaceutical cost management solutions available. One such solution, Pharmacotherapy Review, is ANS’s highly evolved approach to drug utilization review. The Pharmacotherapy Review Program […]

By |June 30th, 2015|Medical Cost Containment, Pharmaceutical Industry|Comments Off on Advanced Strategies for Pharmaceutical Cost Management